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1. Introduction 
Serotonin (5-hydroxytryptamine, 5-HT) was first identified as a powerful vasoconstrictor 
over a century ago (Rapport et al., 1948), and in the past 20 years has been recognized as an 
arterial smooth muscle mitogen (Nemecek et al., 1986). Serotonin is also known to act as a 
monoaminergic neurotransmitter in the brain and gastrointestinal tract, and is involved in a 
variety of functions, such as mood regulation, urine storage and voiding, the regulation of 
sleep and body temperature, food intake, and intestinal motility (Ni & Watts, 2006). 
Serotonin is predominantly synthesized and secreted into the blood stream by 
enterochromaffin cells in the gastrointestinal tract and is rapidly taken up and stored in 
small dense granules in platelets (Fanburg & Lee, 1997). In humans, 90% of the body’s 5-HT 
is located in the intestines, and the rest is present primarily in platelets (89%) and the 
central nervous system (12%) (Fanburg & Lee, 1997). When platelets adhere and aggregate 
at sites of vessel injury, 5-HT is secreted and directly accelerates platelet aggregation (De 
Clerck, 1990; Wester et al., 1992).  
The first step in the synthesis of 5-HT from tryptophan is the enzyme tryptophan 
hydroxylase (TPH), which is also the rate-limiting enzyme in its biosynthesis. TPH is known 
to have two isoforms, TPH-1 and TPH-2, which share an overall identity of approximately 
70% (Walther et al., 2003). TPH-1 is mainly present in the pineal gland, thymus, spleen, and 
enterochromaffin cells of the gastrointestinal tract. TPH-2 is expressed solely in neuronal 
cells, such as the raphe nuclei of the brainstem. Finally, 5-HT is metabolized by monoamine 
oxidase A to form the metabolite 5-hydroxyindole acetic acid. Monoamine oxidase A is an 
intracellular enzyme and 5-HT must first be taken up into the cell prior to metabolism, and 
this achieved via the 5-HT transporter (Ni & Watts, 2006). 
Serotonin is an extracellular mediator recognized by the 5-HT transporter and seven 
different receptors (5-HT15-HT7), giving rise to pleiotropic intracellular responses. All 5-HT 
receptors, with the exception of 5-HT6, are involved in cardiovascular regulation. Central 5-
HT1A, 5-HT3, and 5-HT7 receptors play physiological roles in the regulation of 
cardiovascular reflexes, controlling changes in parasympathetic drive to the heart (Ramage 
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& Villalon, 2008). These reflexes also affect the activity of the sympathetic nervous system, 
which itself can be inhibited by stimulation of central 5-HT1A receptors causing a drop in 
blood pressure and excited by 5-HT2 receptor stimulation resulting in an increase in blood 
pressure. Acute vascular constriction by 5-HT is usually mediated by 5-HT1B and 5-HT2A 
receptors, except in the intracranial arteries in which constriction is mediated only through 
5-HT1B receptors (Kaumann & Levy, 2006). Both 5-HT1B and 5-HT2A receptors can mediate 
coronary artery spasm and pulmonary hypertension. 
Serotonin promotes platelet aggregation and the proliferation, migration, and contraction of 
vascular smooth muscle cells (VSMCs). In addition to physiological hemostasis, these 
vascular responses play pivotal roles in the development and progression of 
atherothrombotic diseases.    
2. Platelet aggregation 
When platelets aggregate, 5-HT is released into the extracellular environment from the 
dense granules of activated platelets. The 5-HT thus released further activates other platelets 
by binding to 5-HT2A receptors on the platelet membrane, contributing to thrombus 
formation (Satoh et al., 2006). Serotonin promotes further platelet recruitment and activates 
the coagulation pathway. The blood vessels in which platelets aggregate are exposed to high 
concentrations of 5-HT (Benedict et al., 1986).  
3. Vasoconstriction 
Serotonin is well known to act as a potent vasoconstrictor and has been shown to cause both 
vasoconstriction and vasodilation by interacting with receptors expressed on VSMCs, 
endothelial cells, or adrenergic nerve endings. In systemic arterial smooth muscle, 5-HT 
induces contractions only at sites of endothelial damage where platelet aggregation occurs, 
and this effect is antagonized by 5-HT2 receptor antagonists (Sigal et al., 1991). Serotonin 
also amplifies the effects of other vasoconstrictors, such as histamine, angiotensin II, 
prostaglandin F2, and noradrenaline (O’Rourke et al., 2006). The potent contractile effect of 
5-HT may contribute to the vasoconstriction of coronary collateral vessels developed by 
reduction of coronary blood flow (Wright et al., 1992) and vasospastic disorders in arteries 
covered with regenerated endothelium and in atherosclerotic arteries (Sobey et al., 1991). 
The blood vessel wall chronically exposed to abnormally high blood pressure is 
characterized by increased vascular responsiveness to 5-HT. Chronic blockade of 5-HT2A 
receptors reduces the development of hypertension in spontaneously hypertensive rats 
(Gradin et al., 1991).  
4. VSMC proliferation 
Serotonin stimulates the migration and proliferation of VSMCs through 5-HT2A receptors 
(Tamura et al., 1997; Pakala et al., 1997, 1999a). Serotonin interacts synergistically with 
atherogenic lipoproteins (low-density lipoprotein [LDL] and β-very low density lipoprotein) 
(Koba et al., 1999, 2000), oxidized LDL and its major components, such as 
lysophosphatidylcholine, 4-hydroxy-2-nonenal, and reactive oxygen species (Watanabe et 
al., 2001a, 2001b) in inducing VSMC proliferation. Serotonin also potentiates the mitogenic 
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effects of other vasoactive agents, such as endothelin-1, angiotensin II, urotensin II, and 
thromboxane A2 (Watanabe et al., 2001c, 2001d, 2001e; Pakala et al. 1997), platelet-derived 
microparticles (Pakala, 2004), coagulation factors, such as thrombin and coagulation factor 
Xa (Pakala & Benedict, 1999; Pakala, 2003), and monocyte chemoattractant protein-1 on 
VSMCs (Watanabe et al., 2001f). In addition, 5-HT stimulates the expression of interleukin-6 
and cyclooxygenase-2 in VSMCs (Ito et al., 2000; Machida et al., 2011). 
5. Endothelial cell function 
Serotonin stimulates the expression of tissue factor and plasminogen activator inhibitor-1 in 
endothelial cells through 5-HT2A receptors (Kawano et al., 2001). Serotonin-stimulated 
endothelial cells secrete a T lymphocyte-specific chemotactic cytokine with competence 
growth factor activity (Katz et al., 1994). Serotonin, alone and combined with thromboxane 
A2, potently induces endothelial cell proliferation (Pakala et al., 1994, 1999b). However, 
there is still controversy regarding the effects of 5-HT on endothelial cell proliferation (Ruiz-
Perez et al., 2011).  
6. Macrophage foam cell formation 
Serotonin stimulates monocyte adhesion (Lorenowicz et al., 2006), and enhances 
macrophage foam cell formation associated with increased uptake of oxidized LDL (Aviram 
et al., 1992) and up-regulation of acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) 
through 5-HT2A receptors (Suguro et al., 2006).  
7. 5-HT2A receptor blockade 
The roles of 5-HT in the pathogenesis of atherothrombotic diseases are revealed by the 
results of pharmacological interventions involving 5-HT2A receptors. Functional analyses of 
the roles of 5-HT in the cardiovascular system using 5-HT2A receptor knockout mice have 
not been performed. Several studies performed before the discovery of specific and/or 
selective 5-HT2A receptor antagonists indicated that 5-HT2 receptor blockers inhibit 
angioplasty-induced vasospasm and microvascular constriction following atherosclerotic 
plaque rupture in atherosclerotic rabbit models (Sigal et al., 1991; Taylor et al., 2004). 
Sarpogrelate, a selective 5-HT2A receptor antagonist, inhibits responses to 5-HT mediated by 
5-HT2A receptors, such as platelet aggregation and thrombus formation (H Hara et al., 1991a; 
Nishihira et al., 2006), and prevents the development of atherosclerotic lesions (H Hara et 
al., 1991b; Hayashi et al., 2003), vasospasm (Miyata et al., 2000), and intimal hyperplasia in 
vein grafts after bypass grafting (Kodama et al., 2009). This drug suppresses ACAT-1 
expression in macrophages (Suguro et al., 2006), vascular oxidative stress and VSMC 
proliferation (Watanabae et al., 2001d; Sun et al., 2011), up-regulates endothelial nitric oxide 
synthase (Hayashi et al., 2003), and reduces the expression of matrix metalloproteinase-1 
that degrades the arterial extracellular matrix (Hayashi et al., 2003), contributing to 
stabilization of vulnerable plaque.  
8. 5-HT concentration and Cardiovascular Disease 
In a previous study involving the measurement of washed platelet-bound 5-HT 
concentration in three groups based on the presence and absence of thrombotic diseases, 
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platelet 5-HT levels were highest in patients with deep-vein thrombosis and pulmonary 
embolism prior to death from thrombotic events. The lowest levels were detected in subjects 
without thrombosis, and intermediate levels were seen in patients with cerebral thrombosis 
(Misra et al., 1975). These findings suggested that 5-HT plays an important role in the 
initiation of thrombus formation.  
With regard to the association between 5-HT and coronary artery disease (CAD), it has been 
reported that coronary sinus plasma samples from CAD patients evoked vasoconstriction, 
whereas systemic artery and venous samples from patients without CAD did not (Rubanyi et 
al., 1987). In addition, the vasoactive activity of the coronary sinus plasma showed a positive 
correlation with the severity and extent of coronary artery narrowing, and among various 
pharmacological interventions only methiothepin, a non-selective 5-HT receptor antagonist, 
prevented the vasoconstriction induced by these coronary sinus plasma samples. Although 
this study did not measure 5-HT concentration directly, these results suggested that the 
amount of 5-HT released into the coronary sinus plays an important role in vasoconstriction in 
the coronary circulation. The first direct measurement of 5-HT concentration in human 
coronary circulation was reported by van den Berg and co-workers (van den Berg et al., 1989), 
who measured 5-HT concentration by modified radioenzymatic assay (Benedict et al., 1986; 
Hussain & Sole, 1981) in platelet-poor plasma obtained from the central aorta and coronary 
sinus of 52 patients referred for cardiac catheterization. The 5-HT concentration in the 
coronary circulation determined by subtracting the levels in the aorta from those in the 
coronary sinus is significantly higher in patients with CAD compared with those without CAD 
(0.6 ± 6.6 ng/ml vs. -5.6 ± 10.3 ng/ml, mean ± SD, p < 0.05). These concentrations were 
significantly higher in CAD patients with complex coronary lesions compared with those with 
smooth concentric lesions (3.1 ± 5.5 ng/ml vs. -1.9 ± 6.6 ng/ml, p < 0.02). A similar method 
was used to measure 5-HT concentration in coronary circulation in 8 patients with CAD 
undergoing plain old balloon angioplasty (POBA) (Golino et al., 1994). The 5-HT levels in the 
coronary sinus increased significantly after POBA, while those in the aorta did not change. 
Coronary constriction distal to the site of dilation observed after POBA was positively 
correlated with the 5-HT concentration in the coronary circulation, and this coronary 
constriction was inhibited by pretreatment with the 5-HT2A receptor antagonist, ketanserin. 
Other studies using similar techniques have shown that the transcardiac 5-HT concentration is 
significantly higher in patients with variant angina pectoris compared with non-CAD controls 
(Murakami et al., 1996, 1998). These studies demonstrated that 5-HT released from activated 
platelets plays an important role in the pathogenesis of CAD in humans. However, the 
methods used in these studies required invasive procedures.  
Vikenes and co-workers measured 5-HT concentrations in platelet rich plasma from venous 
blood using high-performance liquid chromatography (HPLC) in 122 men undergoing 
coronary angiography (Vikenes et al., 1999). Their data indicated that total 5-HT 
concentration was positively correlated with platelet count (r = 0.552, p  < 0.001), and both 
total 5-HT concentration and platelet counts were significantly higher in patients with CAD 
compared with those without CAD. The difference in 5-HT level was greatest in men aged  
60 years old, and the difference reduced steadily with age. The high 5-HT concentration ≥ 1 
mol/l was significantly associated with CAD, with an odds ratio (OR) of 3.84 (95% 
confidence interval [CI] 1.1213.11), independently of age and smoking. During a mean 
follow-up period of 44 ± 15 months, Kaplan-Meier cardiac event-free survival curves for 
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CAD patients aged  70 years old indicated a better prognosis with regard to cardiac events 
for patients with low 5-HT (< 1 mol/l) (log rank test, p < 0.05). Venous plasma 5-HT 
concentration measured by radioimmunoassay was reported to be significantly higher in 
patients with variant angina pectoris than in those with healed myocardial infarction or 
controls (Figueras et al., 2005). On the other hand, comparison of 5-HT concentration in 
platelet-poor plasma and whole blood indicated that plasma 5-HT concentration tended to 
increase with age, while its concentration in whole blood decreased (K Hara et al., 2004). The 
ratio of plasma to whole-blood concentration of 5-HT was significantly higher in various 
types of CAD, such as variant angina pectoris, acute coronary syndrome (ACS), and prior 
myocardial infarction, compared with healthy controls, whereas whole-blood 5-HT levels 
were somewhat higher in healthy controls than in patients with effort angina. The ratio of 
plasma to whole-blood concentration of 5-HT was recently demonstrated to be positively 
correlated with Framingham 10-year risk scores for CAD (Y Hirowatari et al., 2011). These 
clinical studies suggested that high levels of 5-HT are significantly associated with 
atherosclerotic cardiovascular diseases and the occurrence of cardiovascular events. Thus, 5-
HT plays a key role in the pathogenesis of atherothrombosis. 
9. 5-HT2A receptor blocker and treatment of CAD 
Several clinical studies with 5-HT2A receptor blockers have supported the experimental 
results demonstrating that 5-HT plays an important role in the development of CAD due to 
platelet aggregation, VSMC constriction, and migration and proliferation of VSMCs. In a 
study of 22 patients with stable effort angina, oral administration of 200 mg of sarpogrelate 1 
hour prior to treadmill exercise test was shown to improve exercise capacity and the 
severity score determined by myocardial perfusion scintigraphy in 12 patients with well-
developed collateral flow evaluated by coronary angiography, whereas sarpogrelate 
affected neither exercise time nor severity score in other patients without collateral flow 
(Tanaka et al., 1998). This was confirmed in another study involving 2 weeks of treatment 
with 300 mg of sarpogrelate in 20 patients with stable angina pectoris (Kinugawa et al., 
2002); treatment with sarpogrelate significantly increased the specific activity scale score, 
increased exercise time and rate-pressure product, an index of myocardial oxygen 
consumption, at onset of ischemic ST depression  0.1 mV on electrocardiogram, and 
decreased the number of anginal attacks only in patients with angiographically proven well-
developed collateral flow. On the other hand, sarpogrelate showed no effects in the patients 
without well-developed collateral flow. Similar results were obtained in another study with 
intravenous injection of another 5-HT2A receptor antagonist, ketanserin (Kyriakides et al., 
1999). In a study of stable angina pectoris patients with single-vessel disease, ketanserin 
increased coronary collateral blood flow and decreased myocardial ischemia during POBA. 
In a study of 15 CAD patients without significant stenosis (< 75% diameter stenosis) in the 
left anterior descending coronary artery, oral administration of 200 mg of sarpogrelate 
increased the coronary blood flow velocity at both baseline and hyperemia evaluated by 
intracoronary Doppler guidewire without any effects on systemic blood pressure or cardiac 
output (Satomura et al., 2002). On the other hand, there were no significant differences in 
baseline or hyperemic coronary blood flow velocity in the control group. These results 
suggested that sarpogrelate augments coronary flow reserve by inhibiting 5-HT-induced 
coronary vasoconstriction and platelet aggregation in collateral vessels in CAD patients.      
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In a comparative study of the effects of oral administration of sarpogrelate administration 
(200 mg) or placebo in addition to aspirin and ticlopidine 60 minutes before POBA in 20 
patients with stable effort angina with a de novo single stenotic lesion of 75%90%, length < 
20 mm in the proximal left anterior descending coronary artery, sarpogrelate significantly 
reduced the ischemic ST changes after coronary angioplasty compared with the placebo 
group with no changes in collateral blood flow, blood pressure, or heart rate (Horibe et al., 
2004). These observations suggested that sarpogrelate improves myocardial ischemic injury 
by pharmacological ischemic preconditioning rather than by stimulating collateral 
development. 
Studies investigating the effects of 5-HT2A receptor blockers on prevention of restenosis after 
coronary angioplasty yielded conflicting results between ketanserin and sarpogrelate. In a 
small placebo-controlled study, 24-hour infusion of ketanserin following POBA prevented 
the early restenosis evaluated at 24 hours after POBA but failed to prevent restenosis at 4 to 
9 months after POBA (Klein et al., 1990). The Post-Angioplasty Restenosis Ketanserin 
(PARK) study was a randomized, double-blind, placebo-controlled trial to assess the effects 
of ketanserin in prevention of restenosis after POBA (Serruys et al., 1993). A total of 658 
patients with stable or unstable angina pectoris who were scheduled to undergo elective 
POBA received either ketanserin (loading dose, 40 mg 1 hour before POBA; maintenance 
dose, 40 mg bid for 6 months) or placebo. All patients received aspirin for 6 months. The 
primary clinical end points were defined as any one of the following: cardiac death, 
myocardial infarction, or the need for repeat angioplasty or bypass surgery of the previously 
dilated sites between the first POBA and 6 months after POBA. The relative risk of the 
primary end points for the ketanserin group compared with the placebo group was 0.89 
(95% CI 0.701.13). The restenosis rate according to > 50% stenosis and the quantitative 
angiographic findings were similar between the two groups. The PARK study failed to 
show that ketanserin could prevent restenosis and improve clinical outcome after POBA. On 
the other hand, in an investigation of the effects of sarpogrelate in prevention of restenosis 
after coronary stenting in Japanese patients with stable angina pectoris, pretreatment with 
sarpogrelate for 3 days before coronary stenting and continuation of 300 mg of sarpogrelate 
for 6 months in addition to 81 mg of aspirin and 200 mg of ticlopidine markedly reduced 
restenosis rate at 6 months after coronary stenting compared with the non-sarpogrelate 
treatment group (4.3% vs. 28.6%, p < 0.005) (Fujita et al., 2003). The results of multivariate 
logistic regression analysis showed that treatment with sarpogrelate was a significant 
predictor for angiographic restenosis, independent of the findings of quantitative coronary 
angiography, stent characteristics, and the presence of diabetes. These two studies differed 
in 5-HT2A receptor blocker drug characteristics and pretreatment period as well as the 
angioplasty procedure. The latter study supported the suggestion that sarpogrelate may 
prevent the development of intimal hyperplasia due to VSMC proliferation. Further 
randomized controlled trials to investigate the effects of sarpogrelate on prevention of 
restenosis after placement of drug-eluting stents are required.  
10. 5-HT2A receptor blocker and treatment of Peripheral Artery Disease 
Sarpogrelate is widely used clinically as an anti-platelet drug for prevention of thrombosis 
and treatment of critical limb ischemic symptoms in patients with peripheral artery disease 
(PAD), such as arteriosclerosis obliterans (ASO) and Buerger’s disease. In a study by 
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Miyazaki and colleagues (Miyazaki et al., 2007), 22 patients with PAD received either 
sarpogrelate at a dose of 300 mg orally or conventional therapy for 12 weeks. Both forearm 
and leg endothelium-dependent vasodilation were improved and maintained for 24 weeks 
in patients treated with sarpogrelate whereas no improvement was observed in patients 
treated with conventional therapy. In addition, endothelium-nondependent vasodilation 
was similar between the two treatment groups. These results suggest that 12 weeks of 
treatment with sarpogrelate improved vascular endothelial function in PAD patients. 
Further they investigated the effects of a combination of bone marrow mononuclear cell 
implantation and sarpogrelate on endothelial function in 16 PAD patients (Higashi et al., 
2010). They performed the evaluations before and after bone marrow mononuclear cell 
implantation in 16 patients with critical limb ischemia. A 12-week course of sarpogrelate 
treatment amplified the increased leg blood flow responses to acetylcholine evaluated by 
plethysmography induced by bone marrow mononuclear cell implantation compared with 
conventional treatment, whereas bone marrow mononuclear cell implantation improved 
limb ischemic symptoms in the sarpogrealate group as well as in the conventional treatment 
group. These two studies showed that a treatment with sarpogrelate for at least 12 weeks 
has a beneficial effect on vascular endothelial function in PAD patients treated with 
conventional therapy. 
There have been several small studies of the effects of sarpogrelate on various biomarkers 
without controls in PAD patients. In a study of 13 patients with ASO, treatment with 
sarpogrelate for 1 week decreased adenosine diphosphate (ADP)- or collagen-induced 
platelet aggregation and reduced the releases of platelet-derived growth factor, soluble P-
selectin, and transforming growth factor-β1 from platelets stimulated by ADP or collagen 
(Nakamura et al., 2001). In a study of 24 non-diabetic and non-medicated diabetic patients 
with PAD (Fontaine grades 1 and 2), 300 mg of sarpogrelate decreased insulin resistance at 2 
weeks and 3 months after treatment, and increased plasma levels of adiponectin at 3 months 
after treatment (Kokubu, 2006). Similarly, 300 mg of sarpogrelate increased adiponectin 
levels at 2 and 3 months after treatment in 8 diabetic patients with ASO (Yamakawa et al., 
2003). Treatment with 300 mg of sarpogrelate improved limb ischemic symptoms and 
decreased interleukin-18 levels in 8 diabetic patients with ASO (Yamakawa et al., 2004). In a 
study of 10 patients with Buerger’s disease, 8 weeks of treatment with 300 mg of 
sarpogrelate was well-tolerated. However, platelet aggregation induced by 5-HT increased 
significantly after 2 and 4 weeks, and whole-blood 5-HT concentration increased 
significantly after 2 weeks of treatment (Rydzewski et al, 1996).       
11. 5-HT2A receptor blocker and treatment of ischemic cerebrovascular 
disease 
There have been no reports of high plasma 5-HT levels in patients with stroke at the acute 
phase. In a study of elderly subjects, plasma 5-HT concentration measured by enzyme 
immunoassay was significantly higher in patients with vascular dementia caused by stroke 
or atherosclerotic small vessel disease compared with age-matched controls (Ban et al., 
2007). 
In a double-blind, controlled, clinical-pharmacological study, 47 patients with ischemic 
stroke who discontinued any antiplatelet agents and anticoagulants or fibrinolytic agents, 
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were randomly assigned to receive one of three daily doses of sarpogrelate, i.e., 75, 225, or 
300 mg, for 7 days (Uchiyama et al., 2007). Sarpogrelate treatment inhibited platelet 
aggregation induced by 5-HT plus adrenaline in a dose-dependent manner. The 
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary 
Prevention of Cerebral Infarction (S-ACCESS) trial was a randomized, double-blind, 
controlled trial to evaluate and compare the efficacy and safety of sarpogrelate with those of 
aspirin for prevention of recurrence in patients with ischemic stroke (Shinohara et al., 2008). 
A total of 1050 patients with recent ischemic stroke (1 week to 6 months after onset) were 
randomly allocated to receive either 300 mg of sarpogrelate or 81 mg of aspirin with a mean 
duration of follow-up of 1.59 years (maximum: 3.37 years). The annual recurrence rates of 
cerebral infarction were 6.09% (95% CI 4.837.67) with sarpogrelate and 4.86% (3.756.28) 
with aspirin. The hazard ratio (HR) was 1.25 (95% CI 0.891.77); the upper limit of 95% CI of 
the HR exceeded 1.33, indicating that sarpogrelate was slightly inferior to aspirin in 
preventing the recurrence of cerebral infarction. On the other hand, the incidence rates of 
serious vascular events, defined as stroke, ACS, or vascular event-related death, were 
similar between the sarpogrelate and aspirin group. There were significantly fewer bleeding 
events in the sarpogrelate group compared with the aspirin group (11.9%, 95% CI 9.614.4 
vs. 17.3%, 14.720.2, respectively, p < 0.005). In subgroup analysis in the S-ACCESS trial, 
sarpogrelate was shown to be inferior to aspirin in most subgroups except diabetic patients 
(Shinohara & Nishimaru, 2009). Thus, sarpogrelate may be a useful treatment option for 
Japanese stroke patients with diabetes.   
12. Conclusion 
This review presented a discussion of the potential involvement of 5-HT mediated through 
5-HT2A receptors in the development of atherothrombotic cardiovascular diseases, including 
platelet aggregation, thrombus formation, VSMC contraction, and arterial intimal 
hyperplasia. These responses are synergistically augmented with other vasoactive 
compounds, atherogenic lipids, and various inflammatory cytokines. The 5-HT2A receptor 
antagonists inhibit the 5-HT-mediated atherothrombotic process. Although ketanserin 
inhibits not only 5-HT2A receptors but also 1-adrenergic and histamine H1 receptors, it was 
withdrawn due to its tendency to induce proarrhythmia. Sarpogrelate is a specific 5-HT2A 
receptor antagonist that has been reported to have various beneficial effects especially in 
patients with CAD and/or atherosclerotic cardiovascular disease with diabetes, and to have 
fewer adverse effects compared with other anti-platelet agents. However, larger randomized 
controlled trials of sarpogrelate in CAD, PAD, stroke, and diabetes are required.  
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